

THE 2022 MONITORING PROGRAM*



The following substances are placed on the 2022 Monitoring Program:

1. Anabolic Agents:

In and Out-of-Competition: Ecdysterone

2. Beta-2 Agonists:

In and Out-of-Competition: Salmeterol and vilanterol below the *Minimum Reporting Level*.

3. Stimulants:

In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.

4. Narcotics:

In-Competition only: Codeine, hydrocodone and tramadol.

2022年監控計畫*



下列物質列入2022年監控計畫：

1. 同化性製劑：

賽內和賽外： Ecdysterone。

2. 乙二型交感神經致效劑：

賽內和賽外： 低於最低報告濃度之salmeterol 及vilanterol。

3. 興奮劑：

僅賽內： Bupropion、咖啡因、尼古丁、phenylephrine、phenylpropanolamine、pipradrol和synephrine。

4. 麻醉性止痛劑：

僅賽內： Codeine、hydrocodone和tramadol。

*The World Anti-Doping Code (Article 4.5) states: "WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport."

*依世界運動禁藥管制規範（第4.5條）揭示：「世界運動禁藥管制組織應與規範簽署單位及政府協商監控未列在運動禁藥清單之物質，以瞭解運動選手濫用藥物之情形。」